Wordt geladen...
TopBP1 contributes to the chemoresistance in non-small cell lung cancer through upregulation of p53
Resistance to chemotherapeutic drugs is a major obstacle in non-small cell lung cancer (NSCLC) therapy. The molecular determinants of NSCLC resistance to doxorubicin are unknown. In the present study, we investigated whether topoisomerase IIβ binding protein 1 (TopBP1) was involved in the chemoresis...
Bewaard in:
| Gepubliceerd in: | Drug Des Devel Ther |
|---|---|
| Hoofdauteurs: | , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Dove Medical Press
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5042189/ https://ncbi.nlm.nih.gov/pubmed/27729767 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S90705 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|